In Brief: Suspension of Johnson & Johnson COVID-19 Vaccine Lifted (online only)
Date: May 17, 2021
Issue #:
1624Summary:
On April 23, 2021, on advice from the Advisory
Committee on Immunization Practices (ACIP), the
FDA and CDC recommended that use of the Johnson& Johnson adenovirus-based COVID-19 vaccine
resume despite its association with development of
thrombosis with thrombocytopenia syndrome (TTS).
Administration of the vaccine had been paused on April
13 because of 6 reports of TTS, but after completing a
data review that identified a further 9 cases associated
with the formulation, the agencies concluded that the
benefits of the vaccine outweighed its risks. About
7.98 million doses of the single-dose vaccine had been
administered in the US at the time of the review.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: COVID-19 vaccines Source Type: research
More News: Adenoviruses | COVID-19 | Drugs & Pharmacology | Thrombocytopenia | Thrombosis | Vaccines